THIS ISSUE OF THE ARCHIVES provides information about a promising new treatment for age-related macular degeneration (AMD), the major cause of severe and irreversible vision loss in the United States and in many developed countries. The article,1 as well as 2 others published in the September issue of the ARCHIVES,2,3 describes a series of research projects carried out by investigators in North America and Europe to evaluate photodynamic therapy as a treatment for choroidal neovascularization (CNV), the type of late AMD that is the most frequent cause of visual loss to the level of legal blindness and worse.
Fine SL. Photodynamic Therapy With Verteporfin Is Effective for Selected Patients With Neovascular Age-related Macular Degeneration. Arch Ophthalmol. 1999;117(10):1400-1402. doi:10.1001/archopht.117.10.1400